
Myelodysplastic Syndrome - Pipeline Insight, 2024
Description
Myelodysplastic Syndrome - Pipeline Insight, 2024
DelveInsight’s, “Myelodysplastic Syndrome - Pipeline Insight, 2024” report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Myelodysplastic Syndrome: Overview
Myelodysplastic syndrome (MDS) is a heterogeneous group of hematologic neoplasms classically described as a clonal disorder of hematopoietic stem cells leading to dysplasia and ineffective hematopoiesis in the bone marrow. Some patients with MDS may have a transformation into acute myeloid leukemia (AML). MDS is usually diagnosed in older patients over the age of 65. Clinical manifestations include a decrease in the number of red blood cells (RBC), platelets, and white blood cells (WBC). The disease course is variable.
Development of MDS may occur due through various mechanisms such as environmental exposures to chemicals like benzene, radiation, prior exposure to chemotherapeutic agents, or may be idiopathic, which are typically seen in the elderly population. Bone marrow failure syndromes like acquired aplastic anemia and Fanconi anemia have a risk of developing MDS and sometimes mimic this syndrome.
MDS can be de novo or secondary to other causes, also known as treatment-related MDS. Chemotherapeutic agents such as alkylators or topoisomerase II inhibitors have been implicated as known causes of MDS, usually occurring 2 to 7 years after exposure. The mechanism for the development of MDS has been implicated by various genetic and chromosomal abnormalities, which may occur de novo or secondary to one of the above etiologies. Cytogenetic abnormalities are seen in more than 80% of patients and include translocations or more commonly, aneuploidy (loss or gain of a chromosome). Changes in cytogenetics play a large role in the International prognostic scoring system (IPSS). Deletion of the long arm of chromosome 5 (5q) is the most common abnormal karyotype and may be subdivided into 2 categories: treatment-related MDS with 5q deletion, usually with exposure to alkylating agents, versus de novo isolated 5q deletion. Patients with 5q deletion related to prior chemotherapeutic agents usually also have other cytogenetic abnormalities and/or TP53 mutations and usually portends a poor prognosis. Isolated 5q deletion without other cytogenetic abnormalities has a significantly better prognosis. Other cytogenetic abnormalities commonly studied include normal karyotype, deletion 7q (-7), trisomy 8 and –Y.
The mainstay of treatment for MDS involves assessment of symptoms and potential morbidity attributed to the disease. Patients do not always require treatment as long as they are asymptomatic and most can be treated with supportive measures such as intermittent blood or platelet transfusions. MDS often portends an indolent or gradual course, though some patients have risk factors that put them at risk for transformation into AML. Oncologists will use the IPSS or R-IPSS scoring system to help guide the course of treatment. Treatment options include supportive measures, low intensity treatment with systemic agents, or high intensity treatment such as allogeneic stem cell transplant. The only curative modality remains an allogeneic stem cell transplant, but this is often difficult as MDS occurs more commonly in the elderly population. Candidates for allogeneic stem cell transplant must be carefully selected, as the transplant process itself can be morbid for patients with potentially significant treatment-related mortality, especially in the elderly population. However, high-risk patients who are able to undergo transplant have around 50% survival at 3 years. Treatment decisions are often individualized to each patient and based upon potential morbidity and mortality from treatment. Patients in intermediate or high-risk categories are generally considered for treatment.
""Myelodysplastic Syndrome- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myelodysplastic Syndrome pipeline landscape is provided which includes the disease overview and Myelodysplastic Syndrome treatment guidelines. The assessment part of the report embraces, in depth Myelodysplastic Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myelodysplastic Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Myelodysplastic Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Myelodysplastic Syndrome.
This segment of the Myelodysplastic Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Myelodysplastic Syndrome Emerging Drugs
- MBG453: Novartis
- Tamibarotene: Syros Pharmaceuticals
- CA-4948: Curis
- RVU120: Ryvu Therapeutics
Further product details are provided in the report……..
Myelodysplastic Syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Myelodysplastic Syndrome drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Myelodysplastic Syndrome
- There are approx. 120+ key companies which are developing the therapies for Myelodysplastic Syndrome. The companies which have their Myelodysplastic Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Novartis.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Myelodysplastic Syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myelodysplastic Syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myelodysplastic Syndrome drugs.
Myelodysplastic Syndrome Report Insights
- Myelodysplastic Syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Myelodysplastic Syndrome drugs?
- How many Myelodysplastic Syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myelodysplastic Syndrome?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Myelodysplastic Syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Myelodysplastic Syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
- Novartis
- Syros Pharmaceuticals
- Curis
- Ryvu Therapeutics
- Chia Tai Tianqing Pharmaceutical Group
- Amgen
- Sanofi
- Forma Therapeutics
- Agios Pharmaceuticals
- AbbVie
- Daiichi Sankyo Company
- Geron Corporation
- Astex Pharmaceuticals
- Jazz Pharmaceuticals
- Maxinovel Pty., Ltd.
- Mabwell (Shanghai) Bioscience Co., Ltd.
- BeiGene
- Ellipses Pharma
- Treadwell Therapeutics
- Bellicum Pharmaceuticals
- MBG453
- Tamibarotene
- CA-4948
- RVU120
- TQB2618
- AMG 176
- SAR443579
- Etavopivat
- AG-946
- Venetoclax
- Quizartinib
- Imetelstat
- Azacitidine
- Vyxeos
- MAX-40279-01
- 6MW3211
- BGB-11417
- EP0042
- CFI-400945
- BPX-501
Table of Contents
250 Pages
- Introduction
- Executive Summary
- Myelodysplastic Syndrome: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Myelodysplastic Syndrome– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- MBG453: Novartis
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- CA-4948: Curis
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- RVU120: Ryvu Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Myelodysplastic Syndrome Key Companies
- Myelodysplastic Syndrome Key Products
- Myelodysplastic Syndrome- Unmet Needs
- Myelodysplastic Syndrome- Market Drivers and Barriers
- Myelodysplastic Syndrome- Future Perspectives and Conclusion
- Myelodysplastic Syndrome Analyst Views
- Myelodysplastic Syndrome Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.